HOME >> MEDICINE >> NEWS
Kidney disease in diabetics relates to insulins effectiveness, say Pittsburgh researchers

PITTSBURGH, Sept. 1 Insulin resistance, a condition commonly associated with the development of type 2 diabetes, is likely a major cause of kidney disease, or nephropathy, in people with type 1 diabetes, according to study results published by University of Pittsburgh Graduate School of Public Health (GSPH) researchers in the September issue of Kidney International, a journal of the International Society of Nephrology.

"Kidney disease is a major lethal complication for people with diabetes, particularly those with type 1 diabetes, and until now there has been no clear explanation for its cause beyond blood sugar itself," said principal investigator Trevor Orchard, M.D., professor and acting chair, department of epidemiology, GSPH. "We now suspect that reducing or preventing insulin resistance, possibly through exercise, weight loss and drugs, may help people with type 1 diabetes avoid nephropathy."

The study analyzed data from the Pittsburgh Epidemiology of Diabetes Complication Study (PEDCS), a 10-year prospective investigation based on a cohort of adults with type 1, or childhood-onset, diabetes. Of the 658 subjects in PEDCS, 485 did not have nephropathy at baseline and were followed for the current study.

Fifty-six of the 485 subjects developed nephropathy during either the first five years of follow-up, or during years 6-10. Researchers found that in all cases, strong relationships existed between nephropathy and insulin resistance throughout follow up, unlike other risk factors such as blood pressure and blood fats, which only predicted nephropathy in the short term.

To measure insulin resistance, investigators used a novel calculation based on waist-to-hip ratio, hypertension status and long-term blood sugar levels.

"Although our measure of insulin resistance is an estimate based on easier-to-measure factors, it is strongly correlated with the gold standard euglycemic clamp studies and clearly stands out as the leading p
'"/>

Contact: Kathryn Duda
412-624-2607
University of Pittsburgh Medical Center
1-Sep-2002


Page: 1 2

Related medicine news :

1. Kidney cancer surgery safer at high-volume hospitals
2. Kidney transplant patients who develop diabetes show poor short-term outcomes
3. Kidney transplant proposal reduces wait from 24 to 14 months, improves equity for blacks & women
4. Kidney Transplants From Living Donors Reduce Long-Term Costs Of Care
5. The Break Even Cost Of Kidney Transplants Is Shrinking
6. Kidney Transplant Recipients Require Less Long-Term Care If They Receive Well-Matched Donor Organs
7. New Strategy May Succeed At Extending The Life Of Transplanted Kidneys
8. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
9. Maternal Tissue Typing Could Improve Selection Of Kidney Transplant Donors
10. Researchers Begin Drug Trial In Hope Of Finding New Ways To Treat Acute Kidney Failure
11. Organ Rejection Drug Also Shows Promise For The Treatment Of Kidney Disease

Post Your Comments:
(Date:6/19/2013)... The Cancer Support Community (CSC), an international ... for the whole patient with the launch today of ... This inaugural event, held at the Newseum, will feature ... of Congress members who have made a significant impact ... families currently engaged in the cancer journey. ...
(Date:6/19/2013)... Arem Wellness was developed and is managed ... Ridha Arem, who is determined to help educate the ... Arem Wellness provides a monthly newsletter, a blog, many ... well as an exceptional supplement line uniquely designed by ... role diet and nutrition have not only on ...
(Date:6/19/2013)... to the head; a swift jarring to the body and ... It’s understandable, but what else may follow a concussion injury? ... According to mayoclinic.com , usual symptoms that accompany ... other symptoms may follow, sometimes not for days or weeks ... dizziness, feeling like you’re in a fog, light or noise ...
(Date:6/19/2013)... OR (PRWEB) June 19, 2013 To survive when ... Pilot and Vietnam veteran Captain W.S. “Bud” Orr, the most important ... Speaking to host Sharon Kleyne on the Sharon Kleyne Hour Power ... kit in Vietnam, he always placed extra water ahead of guns ... weight limit on survival kits that pilots could carry on planes ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 ... of an Abbreviated New Drug Application (ANDA) for Hydroxyprogesterone ... generic version of Bristol-Myers Squibb’s drug fomerly known as ... to varied inquiries regarding the anticipated approval and market ... product. , Regarding the status of our pending ANDA, ...
Breaking Medicine News(10 mins):Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:Arem Wellness Announces a Recipe Contest 2Health News:Arem Wellness Announces a Recipe Contest 3Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Vietnam Navy Pilot Reveals to Radio Host Sharon Kleyne That He Carried Extra Water Not a Gun in Survival Kit 2Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- In its first major ... company dedicated to advancing development of the ... release drug therapies in patient disease populations ... the acquisition of Enzon Pharmaceutical,s PEGylation Linker ... product pipeline. Acquisition of this technology will ...
(Date:6/19/2013)... , June 19, 2013 Pharma ... new infographic summary of the results from an ... third of all respondents stated that CROs would be an ... of respondents will be running 6 or more clinical trials ... the Clinical Trial Supply USA Summit ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
Cached News: